Back to News
Market Impact: 0.5
Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Corcept Therapeutics said the EMA's Committee for Medicinal Products for Human Use recommended approval of relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The positive CHMP opinion is a major regulatory milestone that advances relacorilant toward European commercialization and could materially expand Corcept's oncology opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
CORT0.82
More News
- Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
- Google's Gemini becomes latest AI model to break out and hack computer systems
- After threatening to seize Greenland by force, Trump agrees to leave it with Denmark and boost military presence. ‘We will be very protective of it!’
- Google’s Gemini AI hacks 3 companies in security test, then stops
- India forces caller-ID apps to feed spam reports to telcos
- Analysis-Russia sanctions bill gives Trump sweeping new tariff powers